New target to wipe pain away mapped

June 5, 2011

Researchers at the Indiana University School of Medicine have discovered a peptide that short circuits a pathway for chronic pain. Unlike current treatments this peptide does not exhibit deleterious side effects such as reduced motor coordination, memory loss, or depression, according to an article in Nature Medicine posted online June 5, 2011.

The peptide, CBD3, has been shown in mice to interfere with signals that navigate to produce pain. Unlike other substances that block pain signals, CBD3 does not directly inhibit the influx of calcium. This is important as influx of calcium regulates heart rhythm and vital functions in other organs.

Rajesh Khanna, Ph.D., assistant professor of pharmacology and toxicology at the Indiana University School of Medicine, said the peptide discovered by him and his colleagues is potentially safer to use than addictive opioids or toxin Prialt®–a recognized analgesic that is injected into the spinal column, both of which can cause respiratory distress, cardiac irregularities and other problems.

"After opioids–the gold standard for pain control -- the next target is calcium channels," said Dr. Khanna. "Along the pain pathway in the spinal cord, there are pain-sensing neurons called nociceptors that have an abundance of calcium channels."

Earlier international research has shown that the calcium channel is a key player within the pathway for pain signals. Based on work from Dr. Khanna's laboratory, it is also accepted that an axonal protein, CRMP-2, binds to the calcium channel "acting like a remote control" to modulate transmission of excitability and , Dr. Khanna explained.

He and his colleagues discovered the CBD3 peptide, a portion of the CRMP-2 protein, realizing that its smaller size would be beneficial in producing a synthetic version for drug development.

CBD3 can be given systemically and blocks pain in a variety of acute as well as chronic pain models, he said. The novel peptide binds to the calcium channel and reduces the number of excitability signals without disrupting the beneficial global calcium flow. Upon reaching the brain, these signals are interpreted as the sensation of pain.

"Since our approach does not directly inhibit calcium entry through voltage-gated channels, we expect that this molecule will be more specific and have fewer side effects than currently available analgesics," said Dr. Khanna. "We anticipate that this peptide will serve as a novel pharmacological therapeutic for the relief of chronic pain."

Explore further: Neuroscientists explain inner workings of critical pain pathway

Related Stories

Neuroscientists explain inner workings of critical pain pathway

February 15, 2007

Whether they're fighting postoperative soreness or relieving chronic discomfort from conditions such as cancer, morphine and other opioids are powerful weapons against pain. Now, in research published online in Nature Neuroscience, ...

Changing 'channels' to eliminate chronic pain

April 26, 2010

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate ...

Recommended for you

Next steps in understanding brain function

August 26, 2016

The most complex piece of matter in the known universe is the brain. Neuroscientists have recently taken on the challenge to understand brain function from its intricate anatomy and structure. There is no sure way to go about ...

Scientists map brain's action center

August 25, 2016

When you reach for that pan of brownies, a ball-shaped brain structure called the striatum is critical for controlling your movement toward the reward. A healthy striatum also helps you stop yourself when you've had enough.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.